The value of remote care in the reduction of healthcare utilization in implantable cardioverter-defibrillator patients

被引:1
|
作者
van Steenbergen, Gijs [1 ]
Ben Jaddi, Oumaima [2 ]
Theuns, Dominic [2 ]
van Veghel, Dennis [1 ]
Dekker, Lukas [1 ,3 ]
Simmers, Tim [1 ]
机构
[1] Catharina Hosp, Catharina Heart Ctr, Eindhoven, Netherlands
[2] Erasmus MC, Thoraxctr, Dept Cardiol, Rotterdam, Netherlands
[3] Eindhoven Univ Technol, Dept Biomed Technol, Eindhoven, Netherlands
来源
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY | 2021年 / 44卷 / 12期
关键词
cardiac resynchronization-therapy; healthcare utilization; implantable cardioverter defibrillator; remote care; telemonitoring; HEART-FAILURE PATIENTS; FOLLOW-UP; ELECTRONIC DEVICES; EXPERT CONSENSUS; MANAGEMENT; EFFICACY;
D O I
10.1111/pace.14390
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Minimal evidence is available of the reduction in healthcare utilization of remote care in ICD patients over a longer period of follow-up. Objectives This study compared healthcare utilization up to 3 year follow-up in implantable cardioverter-defibrillator (ICD) patients with remote care compared to conventional care. Methods We conducted a retrospective cohort study of patients who received a single or dual-chamber ICD or cardiac resynchronization therapy-defibrillator (CRT-D) between 2016 and 2018. Patients with remote care and patients were compared with patients with received conventional care (control group). The primary endpoint was a composite of cardiac follow-up visits, ICD follow-up visits, telephone consultations, emergency department (ED) visits and hospital admissions and was defined as total healthcare utilization. The secondary endpoints were the individual care activities and one-year all-cause mortality. Results A total of 497 patients were included in the study, of which 299 patients were allocated to the remote care and 198 patients to the control group. Mean follow-up was 815 +/- 279 days. Remote care was associated with a significantly lower rate of adjusted total healthcare utilization in comparison to the control group that sustained for 3 subsequent follow-up years (IRR = 0.78, 95% CI [0.67 to 0.92], p < .01). One-year all-cause mortality was similar between the remote care and control group (respectively 3.0% vs. 5.5%, p = .29). Conclusions Compared to the standard follow-up of in-office care, a remote care program was associated with a sustained lower rate of planned and unplanned healthcare utilization up to 3 subsequent years after ICD/CRT-D implantation.
引用
收藏
页码:2005 / 2014
页数:10
相关论文
共 50 条
  • [41] The subcutaneous implantable cardioverter-defibrillator in review
    Kamp, Nicholas J.
    Al-Khatib, Sana M.
    AMERICAN HEART JOURNAL, 2019, 217 : 131 - 139
  • [42] Racial and Ethnic Disparities in Implantable Cardioverter-Defibrillator Utilization: A Contemporary Review
    Tertulien, Tarryn
    Bush, Kelvin
    Jackson, Larry R.
    Essien, Utibe R.
    Eberly, Lauren
    CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE, 2023, 25 (12) : 771 - 791
  • [43] The dilemma of implantable cardioverter-defibrillator therapy in the geriatric population
    Revenco, Diana
    Morgan, James P.
    Tsao, Lana
    JOURNAL OF GERIATRIC CARDIOLOGY, 2011, 8 (03) : 195 - 200
  • [44] Risk of Failure of Transvenous Implantable Cardioverter-Defibrillator Leads
    Borleffs, C. Jan Willem
    van Erven, Lieselot
    van Bommel, Rutger J.
    van der Velde, Enno T.
    van der Wall, Ernst E.
    Bax, Jeroen J.
    Rosendaal, Frits R.
    Schalij, Martin J.
    CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2009, 2 (04) : 411 - 416
  • [45] Prevention of sudden cardiac death by the implantable cardioverter-defibrillator
    Hindricks, Gerhard
    Lenarczyk, Radoslaw
    Kalarus, Zbigniew
    Doering, Michael
    Shamloo, Alireza Sepehri
    Dagres, Nikolaos
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2018, 128 (12): : 764 - 770
  • [46] The subcutaneous implantable cardioverter-defibrillator: A tertiary center experience
    Khazen, Cesar
    Magnusson, Peter
    Flandorfer, Johannes
    Schukro, Christoph
    CARDIOLOGY JOURNAL, 2019, 26 (05) : 543 - 549
  • [47] Secondary prevention implantable cardioverter-defibrillator (ICD) therapy: value in octogenarians
    Christian Hauck
    Andreas Schober
    Alexander Schober
    Sabine Fredersdorf-Hahn
    Ute Hubauer
    Andreas Keyser
    Lars Maier
    Carsten Jungbauer
    Ekrem Ücer
    Aging Clinical and Experimental Research, 2022, 34 : 1073 - 1080
  • [48] The patient perspective on remote monitoring of patients with an implantable cardioverter defibrillator: Narrative review and future directions
    Timmermans, Ivy
    Meine, Matias
    Zitron, Edgar
    Widdershoven, Jos
    Kimman, Geert
    Prevot, Sebastien
    Rauwolf, Thomas
    Anselme, Frederic
    Szendey, Istvan
    Romero Roldan, Javier
    Mabo, Philippe
    Schaer, Beat
    Denollet, Johan
    Versteeg, Henneke
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2017, 40 (07): : 826 - 833
  • [49] Clinical impact of defibrillation testing at the time of implantable cardioverter-defibrillator insertion
    Hadid, Claudio
    Atienza, Felipe
    Strasberg, Boris
    Arenal, Angel
    Codner, Pablo
    Gonzalez-Torrecilla, Esteban
    Datino, Tomas
    Percal, Tamara
    Almendral, Jesus
    Ortiz, Mercedes
    Martins, Raphael
    Martinez-Alzamora, Nieves
    Fernandez Aviles, Francisco
    CARDIOLOGY JOURNAL, 2015, 22 (03) : 253 - 259
  • [50] Characterization of health care utilization in patients receiving implantable cardioverter-defibrillator therapies: An analysis of the managed ventricular pacing trial
    Rickard, John
    Whellen, David
    Sherfesee, Lou
    Peterson, Brett J.
    Nahey, Tara
    Tang, Anthony S.
    Ellenbogen, Kenneth A.
    Cheng, Alan
    HEART RHYTHM, 2017, 14 (09) : 1382 - 1387